HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.

Date publication

avril 2016

Journal

Pharmacogenomics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAHRAM Siamak

Tous les auteurs :
Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, Inoko H, Akbari MT, Noroozi R, Hajilooi M, Solgi G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27020477

Résumé

This study investigated the influence of HLA class-I and -II genes in the response to IFN-β in relapsing-remitting multiple sclerosis (MS) patients.

Mots clés

Adult, Case-Control Studies, Female, HLA-A Antigens, genetics, HLA-B Antigens, genetics, HLA-DRB1 Chains, genetics, Haplotypes, Humans, Interferon beta-1a, therapeutic use, Male, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Prospective Studies

Référence

Pharmacogenomics. 2016 Apr;17(5):489-98